AACR 2024 Transgene et NEC Present Proof of Principle Data for TG4050 in Head & Neck Cancer Donwload Press release (PDF) Interview of Alessandro Riva Donwload the Poster (PDF)

innovation box

Innovative technologies Push the boundaries of immunotherapy Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network. Discover our myvac® platform Discover our invir.IO® platform

TG4001 box

TG4001 A therapeutic vaccine in Phase II TG4001 targets HPV-induced anogenital cancers.   More information


TG4050 One patient, one cancer, one vaccine TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities. TG4050 is being evaluated in a Phase I/II clinical trial.   TG4050 video  Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050,… Continue reading myvac-box


Oncolytic viruses A new generation of products These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer.   Oncolytic viruses video


Transgene in a nutshell Download(PDF)   Corporate Presentation Download(PDF)   Universal Registration Document Download(PDF)

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00


© 2023 Transgene - All rights reserved